My Clinical Approach
Ureteral cancer (UTUC) is rare but aggressive. Modern management is individualized based on EAU risk stratification — preserving renal function in low-risk patients with kidney-sparing, and radical therapy with adjuvant chemotherapy in high-risk patients.
According to EAU UTUC Guidelines 2024 and AUA Bladder Cancer 2024:
- Complete staging: CT urography + ureteroscopy + biopsy + cytology.
- Concurrent cystoscopy — 17% concurrent bladder cancer risk.
- EAU risk stratification for treatment selection.
- Kidney-sparing endoscopic therapy in low-risk patients.
- Robotic nephroureterectomy with bladder cuff in high-risk patients.
- Adjuvant cisplatin-based chemotherapy (POUT) in pT2-T4 or N+.
- Genetic counseling for Lynch syndrome in age <60 or positive family history.
What is UTUC
Upper Tract Urothelial Carcinoma (UTUC) is a malignancy of the upper urinary tract urothelium (renal pelvis + ureter). The majority (95%) are urothelial, less commonly squamous (5%) or adenocarcinoma (<1%). It represents 5-7% of all urothelial cancers. Incidence 1-2/100,000/year. Ureter:pelvis ratio = 1:3.
Important: UTUC coexists with bladder cancer in 17% concurrent and 22-47% after nephroureterectomy — lifelong cystoscopic surveillance is required.
Risk factors
Smoking
The most important modifiable risk factor — increases risk 3-7x. Cessation gradually reduces risk.
Occupational exposure
Aromatic amines (dye, pigment, rubber, petrochemical industries). Latency 20-30 years.
Lynch syndrome (HNPCC)
MMR gene mutations (MLH1, MSH2, MSH6, PMS2). 5-20% of UTUC. Genetic testing if age <60 or family history of colorectal/endometrial cancer.
Analgesic nephropathy
Chronic phenacetin use (withdrawn), excessive paracetamol. Rare in modern Western countries.
Aristolochic acid
Found in Chinese herbal preparations (Aristolochia spp.). Characteristic TP53 mutation. Linked to Balkan endemic nephropathy.
Others
Chronic infection/lithiasis (squamous), renal transplantation (immunosuppression), chronic hepatitis C, high arsenic intake.
Symptoms & clinical presentation
Painless hematuria
Most common symptom (70-80%). Can be macroscopic or microscopic. Usually intermittent — may be ignored.
Flank pain
20-40%. Due to obstruction by tumor or clot, hydronephrosis, or rapid mass growth. Dull ache or colic.
Systemic
Weight loss, cachexia, anorexia, unexplained anemia (especially in advanced disease).
Incidental finding
15% — hydronephrosis/mass on CT/U/S for other reasons. Rare palpable flank mass.
Diagnosis & staging
CT urography (CTU)
Gold standard imaging. Sensitivity 96%, specificity 99%. Provides location, size, invasion, lymph nodes, metastases. Urographic phase shows complete distal field.
MR urography
Alternative in allergy or CKD (eGFR <30). Lower sensitivity for small lesions.
Cystoscopy
Mandatory — 17% concurrent bladder cancer. Allows inspection of external orifices + bladder wash cytology.
Ureteroscopy + biopsy
Diagnostic gold standard. Direct visual inspection + biopsy forceps + selective ureteral cytology. Determines grade and helps risk stratification.
Urine cytology
Sensitivity higher for high-grade (>80%). Adjuncts: BTA test, FISH (UroVysion).
Metastatic staging
Chest CT to rule out pulmonary metastases. Bone scan only if bone pain or elevated ALP.
EAU risk stratification
Low risk (all present)
- • Unifocal lesion
- • Size <2cm
- • Low-grade cytology
- • Low-grade biopsy
- • Papillary morphology
- • No invasion on CT
High risk (any)
- • Hydronephrosis
- • Size >2cm
- • High-grade cytology
- • High-grade biopsy
- • Multifocal
- • Prior radical cystectomy for CIS
- • Sessile / invasive morphology
Treatment (kidney-sparing & radical)
Low risk — Kidney-sparing
Endoscopic management: ureteroscopy + holmium laser ablation. Success 70-90% in papillary low-grade. Continuous surveillance every 3 months.
Segmental ureterectomy: for distal lesions — segmental excision + ureteral reimplantation. Selected cases: equivalent survival to nephroureterectomy.
Intraluminal therapy: mitomycin C (UGN-101 — Jelmyto) or BCG via retrograde infusion or directly into ureter through JJ stent.
High risk — Radical nephroureterectomy
Gold standard. Excision of kidney + entire ureter + bladder cuff (perimeatal bladder area). Laparoscopic or robotic approach comparable to open in oncologic outcomes.
Lymphadenectomy (template-based): for ≥cT2 — improves local control and staging.
Intravesical MMC: single dose of mitomycin C in bladder after nephroureterectomy reduces bladder recurrences (ODMIT-C trial).
Adjuvant chemotherapy (POUT 2020)
4 cycles of gemcitabine + cisplatin for pT2-T4 or N+ after nephroureterectomy. Improves 3-year DFS from 46% to 71% (HR 0.45). New standard of care per EAU 2024.
Metastatic disease
1st line: cisplatin-based (gemcitabine + cisplatin). 2nd line: pembrolizumab, enfortumab vedotin, FGFR3 inhibitor (erdafitinib) in FGFR3+. Modern clinical trials with checkpoint inhibitors.
Follow-up & prognosis
After nephroureterectomy:
- Cystoscopy + cytology every 3 months × 2 years, every 6 months to 5 years, then annually.
- CT thorax/abdomen/pelvis every 6 months × 2 years, then annually.
- eGFR monitoring + protection of contralateral kidney.
After kidney-sparing:
- Ureteroscopy + cytology every 3 months × 1 year, then every 6 months.
- CT urography annually.
5-year survival prognosis: Ta/T1 >80%, T2 60-70%, T3 30-50%, T4 <10%. Early diagnosis is critical.
Frequently Asked Questions (FAQ)
What is ureteral cancer?
Ureteral cancer is part of Upper Tract Urothelial Carcinoma (UTUC), originating from the urothelium of the ureter. >95% are urothelial, less commonly squamous or adenocarcinoma. It represents 5-7% of all urothelial cancers.
What are the risk factors?
Smoking (3-7x risk), exposure to aromatic amines (dyes, rubber industry), analgesic nephropathy (phenacetin), Balkan endemic nephropathy, aristolochic acid (Chinese herbal preparations), Lynch syndrome (HNPCC — 5-20% of UTUC). More common ages 70-90.
What are the symptoms?
Painless macroscopic hematuria (70-80%) — most common symptom. Flank pain (20-40%) from obstruction/hydronephrosis. Palpable mass (10%), rare paraneoplastic syndromes. 15% incidental findings on imaging for other reasons.
How is it diagnosed?
CT urography (gold standard, sensitivity 96%, specificity 99%), ureteroscopy with biopsy and selective ureteral cytology, cystoscopy (rule out concurrent bladder cancer in 17%). Additional: BTA test, FISH cytology.
How is it staged & risk-stratified?
TNM staging: Ta (non-invasive), T1 (subepithelial), T2-T3 (muscle/periureteral), T4 (adjacent organs). EAU risk stratification: low risk (unifocal <2cm, low-grade, papillary) or high risk (multifocal, >2cm, high-grade, invasive, hydronephrosis).
What are treatment options for low risk?
Kidney-sparing therapy: endoscopic management with ureteroscopy + holmium laser ablation, segmental ureterectomy for distal lesions, intraluminal mitomycin C or BCG. Continuous surveillance ureteroscopy every 3-6 months.
What is the high-risk treatment?
Radical nephroureterectomy with bladder cuff excision (perimeatal bladder area) is gold standard. Laparoscopic or robotic approach. Adjuvant chemotherapy with cisplatin regimen (POUT trial) for pT2-T4 or N+. Neoadjuvant chemotherapy considered in selected.
What is the POUT trial?
Phase 3 RCT (Lancet 2020) showing 4 cycles of adjuvant gemcitabine + cisplatin after nephroureterectomy for pT2-T4 or N+ UTUC improved 3-year disease-free survival from 46% to 71% (HR 0.45). Changed standard of care — adjuvant chemotherapy now recommended.
What is the prognosis?
Depends on stage: Ta/T1 5-year survival >80%, T2 60-70%, T3 30-50%, T4 <10%. After nephroureterectomy there is 22-47% risk of bladder cancer recurrence — lifelong cystoscopic surveillance required. Lynch syndrome: tailored genetic counseling.
Related topics
Suspected upper tract cancer?
Contact us for full oncologic evaluation: CT urography, ureteroscopy + biopsy, EAU risk stratification and personalized plan — from kidney-sparing to robotic nephroureterectomy.
Scientific literature
- EAU Guidelines on Upper Urinary Tract Urothelial Carcinoma (2024) — uroweb.org
- Birtle A, Johnson M, Chester J, et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet 2020;395(10232):1268-1277 — pubmed.ncbi.nlm.nih.gov
- Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update. Eur Urol 2023;84(1):49-64 — pubmed.ncbi.nlm.nih.gov
- Kleinmann N, Matin SF, Pierorazio PM, et al. Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101 (OLYMPUS trial). Lancet Oncol 2020;21(6):776-785 — pubmed.ncbi.nlm.nih.gov
- Audenet F, Isharwal S, Cha EK, et al. Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma. Clin Cancer Res 2019;25(3):967-976 — pubmed.ncbi.nlm.nih.gov
Medical Editorship
Dr. Marinos Vasilas, Urologist – Andrologist
Dr. Marinos Vasilas treats UTUC with modern multidisciplinary approach: from individualized EAU risk stratification, kidney-sparing endoscopic therapy (laser, UGN-101), to robotic nephroureterectomy with bladder cuff and adjuvant cisplatin (POUT) per EAU 2024.
View full profile
